Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

About this update from Traws Pharma, Inc.

Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent Advancing clinical candidates for the treatment of hantavirus infections NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today provided recent business highlights and reported financial results for the quarter ended March 31, 2026. The highlights include updates on the Company's lead program, tivoxavir marboxil (TXM), in development for influenza prophylaxis, and its hantavirus drug development efforts. “Q1 2026 was a period of meaningful progress for Traws. The recently announced private financing of up to $60 million in gross proceeds provides us with a clear runway into Q1 2027 and supports our ability to execute on our key programs. We are advancing TXM toward a human challenge trial as a once-monthly prophylactic agent against seasonal influenza, which is scheduled to be initiated in Q2 2026. Separately, we will be actively engaging with the FDA to resolve the clinical hold and enable initiation of global studies by year end,” commented Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “Our pipeline now also includes a potential antiviral therapy for hantavirus. The recent outbreak1 brought new attention to a disease with no approved treatments.” Recent Highlights and Anticipated Milestones: $60 Million Private Financing On April 15, 2026, TRAW announced an up to $60 million private investment in a public equity (PIPE) financing, including $10 million in gross proceeds at closing, with up to approximately $50 million of additional potential gross proceeds from milestone-based and three-year warrants. As described in the Company’s 8K issued on April 15, 2026, the financing consists of the sale of 5,982,919 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.6730 per share. The upfront gross proceeds and milestone-based warrants, along with the current cash and cash equivalents, are estimated to provide sufficient r...

View stock analysis, news, and events for Traws Pharma, Inc.